Novo Nordisk A/s share price logo

Novo Nordisk A/s Share Price

NYSE: NVO

Large Cap

$36.53

-0.55

(-1.48%)

Live

as on

Novo Nordisk A/s Stock Performance

as on March 21, 2026 at 1:07 am IST

  • Day's Low

    Day's High

    $36.32
    $36.75
    downward going graph

    0.57%

    Downside

    0.60%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $35.85
    $81.44
    downward going graph

    1.86%

    Downside

    122.94%

    Upside

    downward going graph

Novo Nordisk A/s share price movements today

Previous Close
$37.08
Open
$36.50
Volume
4.2M
Day's Low - High
$36.32 - $36.75
52 Week Low - High
$35.85 - $81.44

Novo Nordisk A/s Historical Returns

1 Month Return
-21.81 %
3 Month Return
-22.89 %
1 Year Return
-52.94 %
3 Year Return
-48.35 %
5 Year Return
+ 5.42 %

Novo Nordisk A/s Stock Fundamentals & Key Indicators

Check Novo Nordisk A/s market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$166.9B

EPS (TTM)

21.0458

Dividend Yield

1.05%

Quarterly Earnings Growth YOY

-0.05%

PE Ratio (TTM)

10.58

Industry PE ratio

19.807777777777776

PEG Ratio

4.741

EBITDA

153.3B

Revenue (TTM)

309.1B

Profit Margin

33.14%

Return On Equity TTM

60.70%

Novo Nordisk A/s Stock Valuation

Track how Novo Nordisk A/s P/E has moved over time to understand its valuation trends.

Novo Nordisk A/s in the last 5 years

  • Overview

  • Trends

Lowest (2.22x)

December 31, 2025

Today (10.58x)

March 20, 2026

Industry (19.81x)

March 20, 2026

Highest (45.23x)

June 30, 2024

LowHigh

Today’s Price to Earnings Ratio: 10.58x

Novo Nordisk A/s vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Novo Nordisk A/s with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Novo Nordisk A/s image
Novo Nordisk A/s
BUY$166.9B5.42%10.5833.14%
ASTRAZENECA PLC image
ASTRAZENECA PLC
BUY$292.1B283.93%28.8117.41%
Eli Lilly And Company image
Eli Lilly And Company
BUY$821.7B397.86%4031.67%
Johnson & Johnson image
Johnson & Johnson
BUY$571.8B48.46%21.5128.46%
Abbvie Inc image
Abbvie Inc
BUY$368.4B99.41%87.546.91%
See all

Stock Returns calculator for Novo Nordisk A/s Stock including INR - Dollar returns

The Novo Nordisk A/s stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Novo Nordisk A/s investment value today

Current value as on today

₹54,910

Returns

₹45,090

(-45.09%)

Returns from Novo Nordisk A/s Stock

₹53,636 (-53.64%)

Dollar Returns*

₹8,546 (+8.55%)

Analyst Recommendation on Novo Nordisk A/s Stock

Based on 32 analysts

BUY

62.50%

Buy

31.25%

Hold

6.25%

Sell

Based on 32 analysts, 62.5% of analysts recommend a 'BUY' rating for Novo Nordisk A/s. Average target price of $46.94

Novo Nordisk A/s Share Price Target

Get share price movements and forecasts by analysts on Novo Nordisk A/s.

What analysts predicted

22.18%UPSIDE

Target Price

$46.94

Current Price

$36.53

Analyzed by

32 Analysts

Target

$46.94

Novo Nordisk A/s target price $46.94, a slight upside of 22.18% compared to current price of $36.53. According to 32 analysts rating.

Novo Nordisk A/s Stock’s Investor Sentiment and Interest

Investment in Novo Nordisk A/s Shares on INDmoney has grown by 23.21% over the past 30 days, indicating increased transactional activity.

Time period: to

Change:23.21% versus previous 30 day period

Search interest for Novo Nordisk A/s Stock has decreased by -4% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-4% versus previous 30 day period

Novo Nordisk A/s Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
8,408
9,645
9,525
9,818
10,615
12,018
11,320
76,857
74,976
78,434
Gross Profit
7,017
8,179
8,080
8,336
8,931
10,192
9,451
64,011
57,072
63,422
Operating Income
26,913
26,766
31,846
25,934
33,822
36,737
38,791
33,449
23,682
31,624
EBITDA
32,756
28,511
36,906
35,739
37,355
40,298
46,046
43,596
33,761
37,136
Interest Expense
2,168
2,101
2,074
1,562
821
2,817
5,183
4,958
5,007
8,630
Depreciation
2,525
2,992
2,914
8,845
2,150
5,198
3,830
4,833
7,757
5,562
Income Before Tax
28,063
27,620
31,918
25,332
34,384
35,557
37,033
33,805
25,517
33,878
Income Tax Expense
5,585
5,657
6,511
5,282
7,083
7,327
7,999
7,302
5,511
7,228
Net Income
3,218
3,216
3,703
2,892
4,063
3,959
4,209
26,503
20,006
26,650
Net Profit Margin
38.27%
33.35%
38.88%
29.46%
38.28%
32.95%
37.18%
34.48%
26.68%
33.98%

Novo Nordisk A/s Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
15,844
17,755
17,040
18,147
20,749
21,403
25,173
34,014
40,735
297,195
Gross Profit
13,408
14,952
14,356
15,159
17,328
17,807
21,126
28,776
34,490
238,769
Operating Income
48,432
48,967
47,248
52,483
54,126
58,644
74,809
102,574
128,339
129,833
EBITDA
51,056
51,952
51,625
54,434
59,273
65,394
76,802
114,629
137,376
143,936
Interest Expense
65
90
85
494
500
289
378
542
1,640
6,517
Depreciation
-
3,182
3,925
5,661
5,753
6,025
7,362
9,413
19,107
21,982
Income Before Tax
47,798
48,680
47,615
48,553
53,130
59,080
69,062
104,674
127,191
125,526
Income Tax Expense
9,873
10,550
8,987
9,602
10,992
11,323
13,537
20,991
26,203
27,026
Net Income
5,375
6,061
5,886
5,792
6,887
7,259
7,898
12,255
14,165
98,500
Net Profit Margin
33.93%
34.14%
34.54%
31.92%
33.19%
33.92%
31.38%
36.03%
34.78%
33.14%

Novo Nordisk A/s Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
21,963
25,407
20,050
27,301
28,230
29,034
26,503
20,006
26,891
Operating Cash Flow
9,551
14,314
50,503
43,850
12,301
24,591
40,785
46,107
7,619
Investing Cash Flow
-14,717
3,956
-20,731
-20,904
-91,216
-6,673
-14,248
-15,425
-42,812
Financing Cash Flow
-10,116
-26,382
16,683
-18,401
36,835
5,451
-46,230
-17,096
29,467
Change in Cash
-15,491
-8,068
46,497
4,197
-41,363
23,283
-20,503
13,649
-5,620

Novo Nordisk A/s Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
38,130
38,628
38,951
42,138
47,757
55,525
83,683
100,988
102,434
Operating Cash Flow
41,168
44,616
46,782
51,951
55,000
78,887
108,908
120,968
119,102
Investing Cash Flow
-6,571
-12,080
-11,509
-22,436
-31,605
-24,918
-43,892
-128,895
-79,158
Financing Cash Flow
-35,689
-34,521
-35,484
-32,244
-25,493
-51,797
-63,158
8,735
-28,408
Change in Cash
-1,303
-1,529
-218
-3,185
-1,507
1,934
1,739
1,263
10,809

Mutual Funds that own Novo Nordisk A/s Stock

Check out the Mutual Funds with significant holdings in Novo Nordisk A/s.

Global Institutional Holdings in Novo Nordisk A/s

Funds
Holdings
Wells Fargo & Co
0.09%
Capital Research & Mgmt Co - Division 3
0.25%
Ameriprise Financial Inc
0.04%
JPMorgan Chase & Co
0.24%
The Goldman Sachs Group Inc
0.15%
See all

Novo Nordisk A/s News & Key Events

  • img

    Today's Timeline - 19 March

    Thu, 03:08 PM

    -

    Bernstein initiates Novo Nordisk with Underperform rating, citing ongoing pressure in the US market.

    Thu, 07:20 PM

    -

    Novo Nordisk's Wegovy 7.2 mg approved; shares down 2.05% amid market competition.

    Thu, 10:00 PM

    -

    Novo Nordisk's semaglutide patent expiration triggers concerns over market competition and generics.

  • img

    Today's Timeline - 19 March

    Thu, 10:23 PM

    -

    FDA approves higher dose Wegovy to compete with Eli Lilly's Zepbound, launching in April.

Insights on Novo Nordisk A/s

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Novo Nordisk A/S has shown strong profit growth over the last two quarters. Their net profit increased from $20.00 billion to $26.65 billion, marking an average increase of 24.9% per quarter.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Novo Nordisk A/S has seen positive growth in its revenue over the past two quarters. The revenue increased from $74.97 billion to $78.43 billion, representing an average growth of 4.4% per quarter.

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, ASTRAZENECA PLC has given 146.9% return, outperforming this stock by 199.8%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, ASTRAZENECA PLC has given 183.1% return, outperforming this stock by 231.5%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, NVO stock has moved down by -21.8%

About Novo Nordisk A/s

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in nine countries and affiliates or offices in five countries.
OrganisationNovo Nordisk A/s
HeadquartersNovo Alle 1, Bagsvaerd, Denmark, 2880
IndustryHealth Technology
CEOMr. Maziar Mike Doustdar B.A.
E-voting on sharesClick here to vote

Key Management of Novo Nordisk A/s

Name

Title

Mr. Karsten Munk Knudsen

Executive VP, CFO & Member of the Management Board

Mr. Jamey Millar

Executive VP of US Operations & Member of Management Board

Mr. John F. Kuckelman

SVP, Group General Counsel, Global Legal, IP & Security and Member of Management Board

Mr. Emil Kongshoej Larsen

EVP of International Operations & Member of Management Board

Ms. Elin Jager

SVP, Chief of Staff to CEO, Corporate Strategy & Sustainability and Member of Management Board

Ms. Hong Chow

Executive VP of Product & Portfolio Strategy and Member of Management Board

Mr. Maziar Mike Doustdar B.A.

President, CEO & Member of the Management Board

Dr. Martin Holst Lange

EVP of R&D, Chief Scientific Officer and Member of the Management Board

Ms. Tania Sabroe

EVP of People, Organisation and Corporate Affairs & Member of Management Board

Ms. Thilde Hummel Bogebjerg

Executive VP of Enterprise IT & Quality and Member of Management Board

FAQs

What is Novo Nordisk A/s share price today?

Novo Nordisk A/s share price today is $36.53 as on . Novo Nordisk A/s share today touched a day high of $36.75 and a low of $36.32.

What is the 52 week high and 52 week low for Novo Nordisk A/s share?

Novo Nordisk A/s share touched a 52 week high of $81.44 on and a 52 week low of $35.85 on . Novo Nordisk A/s stock price today i.e. is trending at $36.53,which is 55.14% down from its 52 week high and 1.90% up from its 52 week low.

What is Novo Nordisk A/s's market capitalisation today?

Novo Nordisk A/s market capitalisation is $0.17T as on .

How to invest in Novo Nordisk A/s Stock (NVO) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Novo Nordisk A/s on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Novo Nordisk A/s Shares that will get you 0.0411 shares as per Novo Nordisk A/s share price of $36.53 per share as on March 20, 2026 at 7:37 pm IST.

What is the minimum amount required to buy Novo Nordisk A/s Stock (NVO) from India?

Indian investors can start investing in Novo Nordisk A/s (NVO) shares with as little as ₹93.708 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹937.08 in Novo Nordisk A/s stock (as per the Rupee-Dollar exchange rate as on ). Based on Novo Nordisk A/s share’s latest price of $36.53 as on March 20, 2026 at 7:37 pm IST, you will get 0.2737 shares of Novo Nordisk A/s. Learn more about fractional shares .

What are the returns that Novo Nordisk A/s has given to Indian investors in the last 5 years?

Novo Nordisk A/s stock has given 5.42% share price returns and 27.65% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?